JP2013512263A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512263A5
JP2013512263A5 JP2012541335A JP2012541335A JP2013512263A5 JP 2013512263 A5 JP2013512263 A5 JP 2013512263A5 JP 2012541335 A JP2012541335 A JP 2012541335A JP 2012541335 A JP2012541335 A JP 2012541335A JP 2013512263 A5 JP2013512263 A5 JP 2013512263A5
Authority
JP
Japan
Prior art keywords
mitotic checkpoint
schmidt
compounds
present
pharmacological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012541335A
Other languages
English (en)
Japanese (ja)
Other versions
JP5805652B2 (ja
JP2013512263A (ja
Filing date
Publication date
Priority claimed from EP09075527A external-priority patent/EP2343294A1/en
Application filed filed Critical
Publication of JP2013512263A publication Critical patent/JP2013512263A/ja
Publication of JP2013512263A5 publication Critical patent/JP2013512263A5/ja
Application granted granted Critical
Publication of JP5805652B2 publication Critical patent/JP5805652B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012541335A 2009-11-30 2010-11-17 置換トリアゾロピリジン Expired - Fee Related JP5805652B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075527.3 2009-11-30
EP09075527A EP2343294A1 (en) 2009-11-30 2009-11-30 Substituted triazolopyridines
PCT/EP2010/006993 WO2011063907A1 (en) 2009-11-30 2010-11-17 Substituted triazolopyridines

Publications (3)

Publication Number Publication Date
JP2013512263A JP2013512263A (ja) 2013-04-11
JP2013512263A5 true JP2013512263A5 (enExample) 2013-12-26
JP5805652B2 JP5805652B2 (ja) 2015-11-04

Family

ID=42026745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012541335A Expired - Fee Related JP5805652B2 (ja) 2009-11-30 2010-11-17 置換トリアゾロピリジン

Country Status (7)

Country Link
US (1) US8551980B2 (enExample)
EP (2) EP2343294A1 (enExample)
JP (1) JP5805652B2 (enExample)
CN (1) CN102858768B (enExample)
CA (1) CA2781914A1 (enExample)
ES (1) ES2439776T3 (enExample)
WO (1) WO2011063907A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
EP2651950A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP5822944B2 (ja) 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
US20130303532A1 (en) 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
CA2821827A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821817A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9388140B2 (en) 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
JP5951750B2 (ja) 2011-04-06 2016-07-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリジン類およびその中間体
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CA2867061A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
EP2827869A4 (en) 2012-03-23 2015-09-23 Dennis Brown COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGUE THEREOF, WITH MEISOINDIGO
JP6238979B2 (ja) * 2012-07-10 2017-11-29 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジンを調製する方法
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
DK3008062T3 (en) 2013-06-11 2017-06-12 Bayer Pharma AG PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES
US20160128988A1 (en) * 2013-06-11 2016-05-12 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
US11208696B2 (en) 2015-04-17 2021-12-28 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPH0690447B2 (ja) 1986-09-12 1994-11-14 コニカ株式会社 ハロゲン化銀写真感光材料
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5880066A (en) 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
JP2878531B2 (ja) 1991-12-16 1999-04-05 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
WO2003000659A1 (en) 2001-06-26 2003-01-03 Nissan Chemical Industries, Ltd. Heterocycloiminophenyl compounds and fungicides and insecticides for agricultural and horticultural use
ES2359055T3 (es) 2002-09-11 2011-05-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y el tratamiento de tumores.
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1697381A4 (en) * 2003-12-19 2009-03-11 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
AU2006337085B2 (en) 2005-12-27 2013-12-19 Curis, Inc. Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
MX2009002171A (es) 2006-08-30 2009-05-28 Cellzome Ltd Derivados de triazol como inhibidores de cinasas.
EP2468887A1 (en) 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
AU2008277628B2 (en) 2007-07-18 2012-03-15 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
CN103298814A (zh) * 2007-08-23 2013-09-11 阿斯利康(瑞典)有限公司 作为治疗增殖性疾病的ttk/mps1抑制剂的2-苯胺基嘌呤-8-酮
KR20100075881A (ko) 2007-08-31 2010-07-05 메르크 세로노 에스. 에이. 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
US8492356B2 (en) 2007-12-21 2013-07-23 University Health Network Methods of inhibiting tumor growth using TTK antagonists
EP2296475A4 (en) 2008-06-20 2014-03-05 Genentech Inc TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
HRP20160488T1 (hr) 2008-12-19 2016-06-17 Leo Pharma A/S Triazolopiridini kao inhibitori fosfodiesteraze za liječenje kožnih bolesti
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
CA2751517A1 (en) 2009-02-13 2010-08-19 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
EP2424537B1 (en) 2009-04-29 2015-07-08 Bayer Intellectual Property GmbH Substituted imidazoquinoxalines
US8367830B2 (en) 2009-05-20 2013-02-05 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
CA2763900A1 (en) 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
EP2473498A1 (en) 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
WO2011137313A1 (en) 2010-04-30 2011-11-03 Bristol-Myers Squibb Company Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
EP3318561B1 (en) 2010-05-26 2021-12-22 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application

Similar Documents

Publication Publication Date Title
JP2013512263A5 (enExample)
JP2013512268A5 (enExample)
JP2013503824A5 (enExample)
JP2013512264A5 (enExample)
ES2648876T3 (es) Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo
CN101848895B (zh) 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
Jhaveri et al. HSP90 inhibitors for cancer therapy and overcoming drug resistance
EP3746436A1 (en) Fused ring compounds
DOP2019000022A (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
JP2015512943A5 (enExample)
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
JP2016501221A5 (enExample)
JP2017511311A5 (enExample)
NZ628407A (en) Treatment of cancer with tor kinase inhibitors
EP2975938A2 (en) Inhibitors of prmt5 and methods of their use
HRP20171534T4 (hr) Derivati fosfora kao inhibitori kinaza
AU2018212647A1 (en) Combination therapy involving diaryl macrocyclic compounds
JP2015520753A5 (enExample)
JP2021502386A (ja) Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
JP2014508752A5 (enExample)
BR112014027337A2 (pt) composições orgânicas para tratar doenças relacionadas com kras
PH12014501832A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
AU2016301212A1 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
JP2014532751A5 (enExample)
JP2013544892A5 (enExample)